Symbiotec Secures 10-Year Take-or-Pay Alternative Protein CDMO Contract
Symbiotec Pharmalab Ltd 路 Others (Uncategorized) 路 06 Nov 2026, 3:24 pm
Symbiotec Secures 10-Year Take-or-Pay Alternative Protein CDMO Contract Symbiotec Pharmalab entered into a 10-year, take-or-pay CDMO agreement with a European alternative protein innovator to manufacture precision fermentation-based protein. Production will be based at Symbiotec鈥檚 Ujjain campus, utilizing four 100 kL fermenters with integrated downstream processing and quality control. Initial manufacturing will commence at the existing facility, followed by a dedicated plant adding several hundred thousand litres of fermentation capacity, alongside contracted expansion options extending into millions of litres. Financial consideration remains undisclosed due to confidentiality obligations.
Original exchange filing (PDF)
More announcements from Symbiotec Pharmalab Ltd
- Intimation regarding change in Corporate Identification Number (CIN) and Listing Status of the Company. 路 17 Nov 2026
- Transcript of the Earnings conference call for the Analysts and Investors for the Quarter and Half year ended 路 12 Nov 2026
- Pursuant to Regulation 30(6) read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015, as amended from time .... 路 12 Nov 2026
- Pursuant to Part A of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Audio recording of Conference Call for Analysts and Investors held on November .... 路 06 Nov 2026
- The Monitoring Agency report issued by the CARE Edge Ratings, Monitoring Agency, appointed by the Company for the utilisation and application of funds raised through the IPO of the Company .... 路 06 Nov 2026
- The Investor release being issued by the company, for the quarter and half year ended September 30, 2026 路 06 Nov 2026
- Pursuant to regulations 30 of the SEBI Listing Regulations, Investor Presentation on the Unaudited Standalone and Consolidated Financial Results for the Quarter and Half Year ended September 30, 2026. 路 06 Nov 2026
- Symbiotec Pharmalab Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 06 Nov 2026
